Trial Profile
A Pilot Multi-arm Study of sEphB4-HSA in Combination With Different Chemotherapy Regimens in Patients With Specific Advanced or Metastatic Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs SEphB4-HSA (Primary) ; Cisplatin; Docetaxel; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Biliary cancer; Gallbladder cancer; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Aug 2023 Status changed from active, no longer recruiting to discontinued due to lack of funding.
- 05 Aug 2022 Planned End Date changed from 3 Dec 2024 to 3 Sep 2024.
- 05 Aug 2022 Planned primary completion date changed from 28 Feb 2022 to 3 Sep 2023.